STOCK TITAN

[Form 4] Arteris, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.

Arteris, Inc. director Joachim Kunkel received 899 shares of common stock as a fully vested restricted stock award. The award represents retainer fees he chose to take in shares instead of cash.

The grant was based on the average Arteris trading price of $15.98 over the period from February 20, 2026 through April 2, 2026. Following this award, he holds 69,627 shares of Arteris common stock directly. Kunkel elected to defer the receipt of these shares.

Positive

  • None.

Negative

  • None.
Insider Kunkel Joachim
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 899 $0.00 --
Holdings After Transaction: Common Stock — 69,627 shares (Direct)
Footnotes (1)
  1. Fully vested restricted stock. The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. This grant of restricted stock was made on April 5, 2026, based on the average trading price of Arteris, Inc. common stock for the period from February 20, 2026 through April 2, 2026, which was $15.98. The Reporting Person elected to defer the receipt of shares.
Restricted stock award 899 shares Fully vested director retainer grant on April 5, 2026
Reference price $15.98 per share Average trading price February 20, 2026 through April 2, 2026
Holdings after award 69,627 shares Total Arteris common stock directly held by Kunkel after transaction
restricted stock financial
"Fully vested restricted stock. The restricted stock represents retainer fees"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
retainer fees financial
"represents retainer fees that the Reporting Person elected to receive"
elected to defer the receipt of shares financial
"The Reporting Person elected to defer the receipt of shares."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kunkel Joachim

(Last)(First)(Middle)
C/O ARTERIS, INC.
900 E. HAMILTON AVE., SUITE 300

(Street)
CAMPBELL CALIFORNIA 95008

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/05/2026A899(1)(2)A$0.0069,627D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Fully vested restricted stock. The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. This grant of restricted stock was made on April 5, 2026, based on the average trading price of Arteris, Inc. common stock for the period from February 20, 2026 through April 2, 2026, which was $15.98.
2. The Reporting Person elected to defer the receipt of shares.
Remarks:
/s/ Paul Alpern, as Attorney-in-Fact for Kunkel Joachim04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arteris (AIP) director Joachim Kunkel report in this Form 4?

Joachim Kunkel reported receiving 899 shares of Arteris common stock as fully vested restricted stock. These shares represent his director retainer fees, which he elected to take in stock rather than cash, and they increase his direct holdings to 69,627 shares.

How many Arteris (AIP) shares did Joachim Kunkel receive and at what reference price?

He received 899 shares of Arteris common stock as restricted stock. The grant was calculated using an average trading price of $15.98 per share for the period from February 20, 2026 through April 2, 2026, instead of paying his retainer in cash.

Is Joachim Kunkel’s Arteris (AIP) Form 4 transaction a market purchase or sale?

It is not a market purchase or sale. The Form 4 shows a grant of 899 fully vested restricted stock shares as director retainer fees, with a reported price of $0.00 per share, reflecting compensation in equity rather than a cash trade on the open market.

How many Arteris (AIP) shares does Joachim Kunkel hold after this award?

After the reported award, Joachim Kunkel directly holds 69,627 shares of Arteris common stock. This total includes the newly granted 899 fully vested restricted stock shares that he received as retainer fees in lieu of cash for his director service.

Did Joachim Kunkel defer receipt of the Arteris (AIP) restricted stock award?

Yes. A footnote states that Joachim Kunkel elected to defer the receipt of the shares. Although the 899 restricted shares are fully vested and represent his retainer fees, their actual receipt is deferred according to his election under the company’s arrangements.